Research Grade Anti-Human DLL4 Antibody (MLCK-2ABL-001)

Catalog No.

DHJ65306

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1

Clonality

Monoclonal

Target

Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9NR61

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

MLCK-2ABL-001

Targeted delivery of DAPT using dual antibody functionalized solid lipid nanoparticles for enhanced anti-tumour activity against triple negative breast cancer., PMID:39746584

Delta-like ligand 4 inhibitor drug treatment induces pulmonary hypertension in cancer clinical trials., PMID:39525948

Therapeutic Suppression of Atherosclerotic Burden and Vulnerability via Dll4 Inhibition in Plaque Macrophages Using Dual-Targeted Liposomes., PMID:39392531

Astrocytic DLL4-NOTCH1 signaling pathway promotes neuroinflammation via the IL-6-STAT3 axis., PMID:39390606

Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor., PMID:39375952

The Prediction of DLL4 as a Prognostic Biomarker in Patients with Gastric Cancer Using Anti-DLL4 Nanobody., PMID:39046662

Another Notch in the Belt of Rheumatoid Arthritis., PMID:38961731

Molecular hydrogen promotes retinal vascular regeneration and attenuates neovascularization and neuroglial dysfunction in oxygen-induced retinopathy mice., PMID:38915069

COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC., PMID:38861293

Endothelial HIF2α suppresses retinal angiogenesis in neonatal mice by upregulating NOTCH signaling., PMID:38770916

ELTD1 Review: New Regulator of Angiogenesis in Glioma., PMID:38559823

DLL4/Notch blockade disrupts mandibular advancement-induced condylar osteogenesis by inhibiting H-type angiogenesis., PMID:38100236

Notch ligands are biomarkers of anti-TNF response in RA patients., PMID:37796367

Incongruence between transcriptional and vascular pathophysiological cell states., PMID:37745941

Novel specific anti-ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis., PMID:37715566

Notch signaling drives intestinal graft-versus-host disease in mice and nonhuman primates., PMID:37379368

Endothelial-Specific Molecule 1 Inhibition Lessens Productive Angiogenesis and Tumor Metastasis to Overcome Bevacizumab Resistance., PMID:36428773

Notch signaling functions in noncanonical juxtacrine manner in platelets to amplify thrombogenicity., PMID:36190110

Notch Signaling Promotes Mature T-Cell Lymphomagenesis., PMID:36006995

Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study., PMID:35920133

Erratum: Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models., PMID:35812052

Development of anti DLL4 Nanobody fused to truncated form of Pseudomonas exotoxin: As a novel immunotoxin to inhibit of cell proliferation and neovascularization., PMID:35679954

Mycobacterium tuberculosis impedes CD40-dependent notch signaling to restrict Th17 polarization during infection., PMID:35586066

Dll4 Inhibition Promotes Graft Retention in Fat Grafting Enriched with Adipose-Derived Stem Cells., PMID:35579982

Molecular Signature of Antibody-Mediated Chronic Vasculopathy in Heart Allografts in a Novel Mouse Model., PMID:35490714

Anti-Jagged-1 immunotherapy in cancer., PMID:35421813

DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment., PMID:34888208

Reduced Notch1 Cleavage Promotes the Development of Pulmonary Hypertension., PMID:34739767

Delta-like 1-Expressing Cells at the Gland Base Promote Proliferation of Gastric Antral Stem Cells in Mouse., PMID:34438113

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors., PMID:34315767

NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells., PMID:34095881

Porphyromonas gingivalis lipopolysaccharide promotes T-hel per17 cell differentiation by upregulating Delta-like ligand 4 expression on CD14+ monocytes., PMID:33981487

Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4-Notch Signaling to Inhibit Angiogenesis in Lung Cancer., PMID:33628824

Anti-DLL4 ameliorates toluene diisocyanate-induced experimental asthma by inhibiting Th17 response., PMID:33578263

NOTCH signalling in ovarian cancer angiogenesis., PMID:33490217

CircRNA_103765 acts as a proinflammatory factor via sponging miR-30 family in Crohn's disease., PMID:33436852

Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia., PMID:33408769

ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models., PMID:33383646

O-Fucose and Fringe-modified NOTCH1 extracellular domain fragments as decoys to release niche-lodged hematopoietic progenitor cells., PMID:33351914

Dll4 Blockade Promotes Angiogenesis in Nonhealing Wounds of Sox7-Deficient Mice., PMID:33095124

Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models., PMID:32905508

Unique Cholangiocyte-Targeted IgM Autoantibodies Correlate With Poor Outcome in Biliary Atresia., PMID:32767570

Reciprocal communication between astrocytes and endothelial cells is required for astrocytic glutamate transporter 1 (GLT-1) expression., PMID:32650029

DLL4 restores damaged liver by enhancing hBMSC differentiation into cholangiocytes., PMID:32622343

Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer., PMID:32580836

CD28 Signaling Drives Notch Ligand Expression on CD4 T Cells., PMID:32457739

Heritable modifiers of the tumor microenvironment influence nanoparticle uptake, distribution and response to photothermal therapy., PMID:32373218

CAFs-derived MFAP5 promotes bladder cancer malignant behavior through NOTCH2/HEY1 signaling., PMID:32293074

Dll4 Suppresses Transcytosis for Arterial Blood-Retinal Barrier Homeostasis., PMID:32078435

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial., PMID:32037195

Document Download

Research Grade Anti-Human DLL4 Antibody (MLCK-2ABL-001).pdf